SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

 

US FDA outlines new data requirements for HIV vaccine developers

By Zachary Brennan , 04-Mar-2014
Last updated on 04-Mar-2014 at 10:36 GMT

FDA: HIV vaccine firms should provide genotypic data, among other info
FDA: HIV vaccine firms should provide genotypic data, among other info

The US FDA outlined in draft guidance the ways in which sponsors must submit data for their HIV vaccines and other treatments.

The draft guidance, called the "Guidance on Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency," encourages sponsors to use the following sample format for submitting HIV-1 resistance data: One dataset combining patient data, endpoint data, genotypic data, and phenotypic data.

Other subdivisions of data can be based on clinical study, baseline isolates, or virologic failure isolates, though the subdivisions should be discussed with the Division of Antiviral Products (DAVP) before submission.

The guidance focuses on seven key areas:

VI. Co-Receptor Usage;

V. Protease Cleavage Sites;

IV. Phenotypic Data;

III. Genotypic Data;

II. Endpoint Data; and

I. Patient Data.

To identify any potential formatting problems as early as possible, all sponsors are encouraged to submit preliminary (or mock) resistance datasets to the DAVP before assembling formal clinical trial resistance datasets,” the agency says.

Genotypic data should be provided on the corresponding record for each patient isolate for baseline isolates of all patients in treatment-experienced studies, and the endpoint isolates of patients who are classified as virologic failures and discontinuations in all studies. In treatment-naïve studies, a baseline sample should be collected and stored from all patients for future phenotypic and genotypic analysis of virologic failures.

Genotypic data also should be provided for the HIV-1 target, one amino acid per column, with the wild-type (WT) amino acid in the column heading. Changes from WT standard sequence should be indicated in the row.

Sponsors collecting and submitting next generation sequencing (NGS) data should consult with DAVP early in the experimental design process, as additional guidance will be necessary. To initiate discussions with DAVP, sponsors should provide the details of their planned NGS

This guidance is being revised to provide the current format, recommended definitions, standardization of column headings and variables, and recommended data for submission of HIV resistance datasets. To initiate discussions with DAVP, sponsors should provide the details of their planned NGS analyses, including the performance characteristics of the assay and bioinformatics software to be used for analysis.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry